Business Wire06.07.18
NinePoint Medical Inc, a medical device company pioneering the use of Optical Coherence Tomography (OCT) for gastrointestinal applications, has announced a long-term strategic partnership with Merit Medical Systems Inc. This partnership includes a strategic investment and a worldwide distribution agreement with Merit Medical’s endoscopic division, Merit Medical Endotek (Endotek), for NinePoint Medical’s NvisionVLE Imaging System with Real-time Targeting.
This partnership combines the gastrointestinal (GI) and pulmonary medical devices from Endotek with the Advanced OCT platform from NinePoint Medical. This OCT platform has, in a short period of time, become a primary imaging device used by many of the leading hospitals in the United States to aid in the early detection of esophageal cancer.
“NinePoint Medical is committed to providing GI physicians an elegant and cost-effective OCT imaging solution to enable early and accurate diagnosis,” commented Christopher R. von Jako, Ph.D., president and CEO of NinePoint Medical. “Merit Medical Endotek is the ideal partner as they have the reputation, clinical experience, and complementary product portfolio to grow this business.”
“We are very excited to form this partnership in order to provide NinePoint Medical’s OCT imaging system to our customers and other clinicians around the world,” said Merit Medical System’s Chairman and CEO Fred P. Lampropoulos. “Endotek is a market leader in GI solutions, and we share NinePoint Medical’s vision of improving early cancer detection and thereby improving patient outcomes while reducing healthcare costs.”
The NvisionVLE Imaging System provides a clinically valuable new perspective on esophageal disease—the ability to image within the wall of the esophagus. By providing a high-resolution, real-time scan of the esophagus using Optical Coherence Tomography (OCT)—a technology similar to ultrasound but using infrared light rather than sound waves—the system enables physicians to view structures not evident with conventional imaging, and potentially identify disease that would have otherwise been missed. With the recent addition of a Real-time Targeting feature, physicians can not only locate, but now mark areas of interest. This marking feature, in combination with an improved workflow, enables more accurate targeting, potentially leading to improved diagnosis and more effective therapeutic decisions for patients.
The NvisionVLE Imaging System has been cleared by the U.S. Food and Drug Administration and is commercially available in the United States. It is indicated for use as an imaging tool in the evaluation of human tissue microstructure, including esophageal tissue microstructure, by providing two-dimensional, cross-sectional, real-time depth visualization and may be used to mark areas of tissue.
NinePoint Medical is a privately-held medical device company that designs, manufactures, and sells an Optical Coherence Tomography (OCT) imaging platform for clinical use in gastroenterology, pulmonology, urology, gynecology, and ENT, for the evaluation of human tissue microstructure. Using proprietary imaging and software technology, the company is committed to enabling quicker diagnosis of disease and more effective treatments, while reducing the overall cost of healthcare. NinePoint Medical is located in suburban Boston, Mass.
Founded in 1987, Merit Medical Systems Inc. develops, manufactures, and distributes proprietary disposable medical devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales force totaling approximately 290 individuals. Merit employs approximately 5,000 people worldwide with facilities in South Jordan, Utah; Pearland, Texas; Richmond, Va.; Malvern, Pa.; Rockland, Mass.; San Jose, Calif.; Maastricht and Venlo, The Netherlands; Paris, France; Galway, Ireland; Beijing, China; Tijuana, Mexico; Joinville, Brazil; Markham, Ontario, Canada; Melbourne, Australia; Tokyo, Japan; and Yishun, Singapore.
This partnership combines the gastrointestinal (GI) and pulmonary medical devices from Endotek with the Advanced OCT platform from NinePoint Medical. This OCT platform has, in a short period of time, become a primary imaging device used by many of the leading hospitals in the United States to aid in the early detection of esophageal cancer.
“NinePoint Medical is committed to providing GI physicians an elegant and cost-effective OCT imaging solution to enable early and accurate diagnosis,” commented Christopher R. von Jako, Ph.D., president and CEO of NinePoint Medical. “Merit Medical Endotek is the ideal partner as they have the reputation, clinical experience, and complementary product portfolio to grow this business.”
“We are very excited to form this partnership in order to provide NinePoint Medical’s OCT imaging system to our customers and other clinicians around the world,” said Merit Medical System’s Chairman and CEO Fred P. Lampropoulos. “Endotek is a market leader in GI solutions, and we share NinePoint Medical’s vision of improving early cancer detection and thereby improving patient outcomes while reducing healthcare costs.”
The NvisionVLE Imaging System provides a clinically valuable new perspective on esophageal disease—the ability to image within the wall of the esophagus. By providing a high-resolution, real-time scan of the esophagus using Optical Coherence Tomography (OCT)—a technology similar to ultrasound but using infrared light rather than sound waves—the system enables physicians to view structures not evident with conventional imaging, and potentially identify disease that would have otherwise been missed. With the recent addition of a Real-time Targeting feature, physicians can not only locate, but now mark areas of interest. This marking feature, in combination with an improved workflow, enables more accurate targeting, potentially leading to improved diagnosis and more effective therapeutic decisions for patients.
The NvisionVLE Imaging System has been cleared by the U.S. Food and Drug Administration and is commercially available in the United States. It is indicated for use as an imaging tool in the evaluation of human tissue microstructure, including esophageal tissue microstructure, by providing two-dimensional, cross-sectional, real-time depth visualization and may be used to mark areas of tissue.
NinePoint Medical is a privately-held medical device company that designs, manufactures, and sells an Optical Coherence Tomography (OCT) imaging platform for clinical use in gastroenterology, pulmonology, urology, gynecology, and ENT, for the evaluation of human tissue microstructure. Using proprietary imaging and software technology, the company is committed to enabling quicker diagnosis of disease and more effective treatments, while reducing the overall cost of healthcare. NinePoint Medical is located in suburban Boston, Mass.
Founded in 1987, Merit Medical Systems Inc. develops, manufactures, and distributes proprietary disposable medical devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales force totaling approximately 290 individuals. Merit employs approximately 5,000 people worldwide with facilities in South Jordan, Utah; Pearland, Texas; Richmond, Va.; Malvern, Pa.; Rockland, Mass.; San Jose, Calif.; Maastricht and Venlo, The Netherlands; Paris, France; Galway, Ireland; Beijing, China; Tijuana, Mexico; Joinville, Brazil; Markham, Ontario, Canada; Melbourne, Australia; Tokyo, Japan; and Yishun, Singapore.